Home > Back to Publisher > Report Information

Global Pharmaceutical Biotech Market 2010-2025

Visiongain
December 18, 2009
151 Pages - SKU: VSG2582025

Abstract Table of Contents Related Reports

Countries covered: Global

Global Pharmaceutical Biotech Market 2010-2025

The global pharmaceutical biotech market continues to experience high growth, with developers ranging from major pharmaceutical companies to specialist pharmaceutical firms. Significant R&D efforts and innovative new treatments will lead to further expansion of the pharma biotech market. This new report - Global Pharmaceutical Biotech Market 2010-2025 - explains why that market will expand, revealing where the most exciting developments will lie.

This report examines markets for the following therapy classes:

Oncology
Insulins
Immunosuppressive agents
Autoimmune agents
Erythropoietin products
Immunostimulating agents
Interferons
Pure vaccines
Blood coagulation factors
Growth hormones.

Which therapy classes will lead the pharma biotech market in future? Where will the best commercial opportunities lie from 2010 onwards? What are the most-crucial drivers and restraints in this increasingly-important market? This report will provide you with the information that you need to understand current trends and future directions in the global biopharma sector, seeing how it will further bolster the global pharma industry and market. In particular, we discuss prospects for the following products:

Enbrel
Remicade
Avastin
Humira
MabThera
Herceptin
Lantus
Neulasta
Glivec
Epogen.

Comprehensive analysis of the global biopharma market:

Global Pharmaceutical Biotech Market 2010-2025 critically examines that sector through a comprehensive review of information sources and original analysis. The report provides detailed sales forecasts, market share analyses, discussions of pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 100 tables and figures included. The result is a comprehensive market- and industry-centred study, with detailed analyses to benefit your work.

Why you should buy Global Pharmaceutical Biotech Market 2010-2025?

In this report you will receive the following benefits in particular:

You will assess the current market for pharma biotech products
You will review the overall pharma biotech market, including a global sales forecast for 2010 to 2025
You will receive sales forecasts for the ten leading biotech therapy classes from 2010 to 2025, with detailed discussions
You will receive sales forecasts for the leading products in this market from 2010 to 2025, with detailed discussions of market potential and competition
You will receive sales forecasts for leading geographical markets from 2010 to 2025, with informed discussion
You will examine commercial drivers and restraints in depth, exploring their significance
You will discover the most-exciting pipeline developments in the sector, across a range of therapy classes.
Market growth, novel technologies and expansion into new therapeutic areas - our latest report examines the significant technological and commercial opportunities in the global biopharma market.

Nobody with an interest in the pharmaceutical biotech market should overlook this new study. We predict that total revenues will increase throughout our forecast period, 2010 to 2025. With new and increasingly innovative products and a strong pipeline, this crucial pharma sector holds high potential. Do you want to harness those opportunities?

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

1. Executive Summary: 1.1 Global Biotech Market Review; 1.2 Aims, Scope and Format of the Report
2. An Introduction to Biotechnology: 2.1 What is Biotechnology?; 2.2 The Power of Biopharmaceuticals: Turning Medicine around Therapeutically and Commercially; 2.3 Biotechnologies and their Applications in Pharmaceutical Medicine; 2.4 The Future Biopharmaceutical Market; 2.5 Proteomics Constitutes the Next Step after Genomics; 2.6 The Human Genome Project (HGP) and its Influence on Biotechnology
3. The Global Pharmaceutical Biotech Market, 2010-2025: 3.1 The Global Pharmaceutical Biotech Market in 2009; 3.2 The Pharmaceutical Biotech Market Out-Performs the Overall Pharmaceutical Market; 3.3 The Global Pharmaceutical Biotech Market Forecast, 2010-2025; 3.4 The Leading Biotech Therapy Classes, 2010-2025; 3.5 The Oncology Class will Have the Greatest Market Share, 2010 to 2025.; 3.6 Blockbuster Biotech Drugs in 2009; 3.7 Which Drugs Will Show the Greatest Increases in Market Share?
4. The Leading Biotech Therapy Classes, 2010-2025: 4.1 The Top 10 Biotech Therapy Classes in 2009; 4.2 The Oncology Class Currently Leads the Biotech Market; 4.3 Will the Insulins Class Exhibit Strong Growth?; 4.4 Immunosuppressive Agents, 2010-2025; 4.5 The Autoimmune Agents Class Will Show Initial Growth - Will it Last?; 4.6 Erythropoietin Products - How Will Reported Safety Affect Sales?; 4.7 Immunostimulating Agents - Will These Show Increase in Growth?; 4.8 The Interferons Class: Sales, 2010-2025; 4.9 Pure Vaccines: Sales, 2010-2025; 4.10 Blood Coagulation Factors - Will These Show Steady Growth?; 4.11 Growth Hormones Forecast, 2010-2025; 4.12 Chapter Summary: The Top 10 Biotech Therapy Classes, 2010-2025
5. The Leading Pharma Biotech Products, 2010-2025: 5.1 The 10 Leading Biotech Drugs Accounted for 40% of the Global Pharma Biotech Market Sales in 2009; 5.2 Enbrel (Etanercept); 5.3 Remicade (Infliximab); 5.4 Avastin (Bevacizumab); 5.5 MabThera/ Rituxan (Rituximab); 5.6 Humira (adalimumab); 5.7 Herceptin (Trastuzumab); 5.8 Lantus (Insulin Glargine); 5.9 Neulasta (Pegfilgrastim); 5.10 Glivec (Imatinib); 5.11 Epogen, Procrit (Epoetin Alfa); 5.12 Chapter Summary - The Top 10 Leading Biotech Products, 2010-2025
6. Leading Companies in the Pharma Biotech Market: 6.1 The Top Ten Pharma Biotechnology Companies Globally; 6.2 Amgen - The Leading Pharma Biotech Company; 6.3 Other Leading Companies in the Biotech Market; 6.4 Leading Pharma Companies - Biotech Mergers and Acquisitions; 6.5 The Continuing Success of Multinational Biopharmaceutical Companies is Dependent upon Important Drivers and Restraints; 6.6 Companies are Changing their Strategic Focus to Overcome Challenges in the Worldwide Market
7. Issues Affecting the Pharma Biotech Sector: 7.1 SWOT Analysis of the Global Pharma Biotech Sector; 7.2 Market Drivers; 7.3 Market Restraints; 7.4 The Biotech Market is Rapidly Expanding; 7.5 The Benefits of Biotechnological Drugs; 7.6 Access to Capital; 7.7 R&D in Biopharma; 7.8 Regulatory Issues; 7.9 Biotech's Delivery Challenge; 7.10 Increasing Capacity for Biotech Manufacturing; 7.11 The Costs of Biopharmaceuticals; 7.12 Time Taken to Develop a Biotech Drug; 7.13 Significant Future Biopharma Innovation will Result from Academia; 7.14 The Risky Path from Bench to Market; 7.15 Biogeneric Threats; 7.16 Dependence upon Venture Capital Investment; 7.17 Challenges and Issues for the Future Biotech Industry
8. Global Pharma Biotech Market by Region: 8.1 The World Pharma Biotech Market is Dominated by the US; 8.2 The Japanese, Latin American and European Biotech World Market Shares are set to Increase by 2015; 8.3 The US Biotech Market Will Retain its World Dominance
9. The Pharma Biotech R&D Pipeline: 9.1 Technology Driving Biotech Pipeline; 9.2 The Late-Stage Biotech Oncology Pipeline; 9.3 The Late-Stage Human Insulin Pipeline; 9.4 The Late-Stage Immunosuppressive Agents Pipeline; 9.5 The Late-Stage Autoimmune Agents Pipeline; 9.6 The Late-Stage Erythropoietin Products Pipeline; 9.7 The Late-Stage Immunostimulating Agents Pipeline; 9.8 The Late-Stage Interferons Pipeline; 9.9 The Late-Stage Pipeline for Pure Vaccines; 9.10 The Late-Stage Pipeline for Blood Coagulation Factors; 9.11 The Late-Stage Pipeline for Growth Hormones; 9.12 The Future of Biotech R&D
10. Venture Capital Investment in Healthcare Biotechnology: 10.1 What is Venture Capital Investment?; 10.2 What Do VC's Offer?; 10.3 What Do Venture Capitalists Do?; 10.4 Who are Venture Capitalists for Healthcare?; 10.5 Why Do Many Biotech Companies Need VC Funding?
11. Biosimilar Drugs: 11.1 The Emergence of Biosimilars (Follow-on Biologics); 11.2 Improved Technology Has Strengthened the Case for Biosimilars; 11.3 Bioequivalence Will Remain Challenging; 11.4 Biotech Drugs are Expensive to Produce; 11.5 Regulators and Patients are Cautious over Safety; 11.6 The Next Generation of Biotech Drugs Will Restrain Growth in Biosimilars; 11.7 Regulations are the Main Concern for Biosimilars; 11.7.1 FDA Biogeneric/Biosimilar Approval Pathway?; 11.8 The Key Question for Biosimilars
12. Conclusions: 12.1 The Global Biotech Market: Summary; 12.2 The Top 10 Biotech Products of 2009 Achieved Impressive Sales Results; 12.3 Nine of the Current Top 10 Therapy Classes Will Show Growth in Future; 12.4 Market Drivers; 12.5 Market Restraints; 12.6 Growth of the Biopharma Market Will Continue
List of Tables: Table 2.1 Definitions of Selected Biopharmaceuticals; Table 2.2 Summary of Biotechnologies, 2009; Table 3.1 Global Pharmaceutical Biotech Sales Forecast ($bn), 2010-2016; Table 3.2 Global Pharmaceutical Biotech Sales Forecast ($bn), 2017-2025; Table 3.3 Leading Biotech Therapy Classes Sales Forecast ($bn), 2010-2016; Table 3.4 Leading Biotech Therapy Classes Sales Forecast ($bn), 2017-2025; Table 3.5 Market Shares (%) of the Leading Therapeutic Classes, 2009, 2015 and 2025; Table 3.6 Leading Biotech Drugs Sales Forecast ($m), 2010-2016; Table 3.7 Leading Biotech Drugs Sales Forecast ($m), 2017-2025; Table 3.8 Market Shares (%) of the Top Ten Drugs, 2009, 2015 & 2025; Table 4.1 Oncology Class Sales Forecast ($bn), 2010-2016; Table 4.2 Oncology Class Sales Forecast ($bn), 2017-2025; Table 4.3 Human Insulins Class Sales Forecast ($bn), 2010-2016; Table 4.4 Human Insulins Class Sales Forecast ($bn), 2017-2025; Table 4.5 Immunosuppressive Agents Class Sales Forecast ($bn), 2010-2016; Table 4.6 Immunosuppressive Agents Class Sales Forecast ($bn), 2017-2025; Table 4.7 Autoimmune Agents Class Sales Forecast ($bn), 2010-2016; Table 4.8 Autoimmune Agents Class Sales Forecast ($bn), 2017-2025; Table 4.9 Erythropoietin Products Class Sales Forecast ($bn), 2010-2016; Table 4.10 Erythropoietin Products Class Sales Forecast ($bn), 2017-2025; Table 4.11 Immunostimulating Agents Class Sales Forecast ($bn), 2010-2016; Table 4.12 Immunostimulating Agents Class Sales Forecast ($bn), 2017-2025; Table 4.13 Interferons Class Sales Forecast ($bn), 2010-2016; Table 4.14 Interferons Class Sales Forecast ($bn), 2017-2025; Table 4.15 Pure Vaccines Class Sales Forecast ($bn), 2010-2016; Table 4.16 Pure Vaccines Class Sales Forecast ($bn), 2017-2025; Table 4.17 Blood Coagulation Factors Class Sales Forecast ($bn), 2010-2016; Table 4.18 Blood Coagulation Factors Class Sales Forecast ($bn), 2017-2025; Table 4.19 Growth Hormones Class Sales Forecast ($bn), 2010-2016; Table 4.20 Growth Hormones Class Sales Forecast ($bn), 2017-2025; Table 4.21 Top 10 Classes, Rank Comparison, 2009, 2015 & 2025; Table 5.1 Enbrel Sales Forecast ($m), 2009-2016; Table 5.2 Enbrel Sales Forecast ($m), 2017-2025; Table 5.3 Remicade Sales Forecast ($m), 2010-2016; Table 5.4 Remicade Sales Forecast ($m), 2017-2025; Table 5.5 Avastin Sales Forecast ($m), 2009-2016; Table 5.6 Avastin Sales Forecast ($m), 20017-2025; Table 5.7 MabThera/Rituxan Sales Forecast ($m), 2009-2016; Table 5.8 MabThera/Rituxan Sales Forecast ($m), 2017-2025; Table 5.9 Humira Sales Forecast ($m), 2009-2016; Table 5.10 Humira Sales Forecast ($m), 2017-2025; Table 5.11 Herceptin Sales Forecast ($m), 2009-2016; Table 5.12 Herceptin Sales Forecast ($m), 2017-2025; Table 5.13 Lantus Sales Forecast ($m), 2009-2016; Table 5.14 Lantus Sales Forecast ($m), 2017-2025; Table 5.15 Neulasta Sales Forecast ($m), 2009-2016; Table 5.16 Neulasta Sales Forecast ($m), 2017-2025; Table 5.17 Glivec Sales Forecast ($m), 2009-2016; Table 5.18 Glivec Sales Forecast ($m), 2017-2024; Table 5.19 Epogen Sales Forecast ($m), 2009-2016; Table 5.20 Epogen Sales Forecast ($m), 2017-2025; Table 5.21 Top 10 Products: Ranked Comparison, 2009, 2015 & 2025; Table 6.1 The Top 10 Biotech Companies: Revenues ($m) and Market Shares (%), 2008; Table 7.1 SWOT Analysis of the Global Pharma Biotech Market, 2010-2025; Table 8.1 Global Market Shares (%) & Revenues ($m) by Region/Country, 2009; Table 8.2 Pharma Biotech Sales Forecast ($m) by Country/Region, 2010-2016; Table 8.3 Pharma Biotech Sales Forecast ($m) by Country/Region, 2017-2025; Table 8.4 Market Shares (%) by Country/Region, 2009, 2015 & 2025; Table 9.1 The Late-Stage Oncology Pipeline, 2009; Table 9.2 The Late-Stage Human Insulins Pipeline, 2009; Table 9.3 The Late-Stage Immunosuppressive Agents Pipeline, 2009; Table 9.4 The Late-Stage Autoimmune Agents Pipeline, 2009; Table 9.5 The Late-Stage Erythropoietin Products Pipeline, 2009; Table 9.6 The Late-Stage Immunostimulating Agents Pipeline, 2009; Table 9.7 The Late-Stage Interferons Pipeline, 2009; Table 9.8 The Late-Stage Pipeline for Pure Vaccines, 2009; Table 9.9 The Late-Stage Pipeline for Blood Coagulation Factors, 2009; Table 9.10 The Late-Stage Pipeline for Growth Hormones, 2009
List of Figures: Figure 3.1 Global Pharmaceutical Biotech Sales Forecast ($bn), 2010-2025; Figure 3.2 Leading Biotech Therapy Classes (Sales in $m), 2010-2025; Figure 3.3 Market Shares (%) of the Leading Therapy Classes, 2009; Figure 3.4 Market Shares (%) of the Leading Therapy Classes, 2015; Figure 3.5 Market Shares (%) of the Leading Therapy Classes, 2025; Figure 3.6 Top 10 Biotech Drugs Market Shares (%), 2009; Figure 3.7 Top 10 Biotech Drugs Market Shares (%), 2015; Figure 3.8 Top Ten Biotech Drugs Market Shares (%), 2025; Figure 4.1 Oncology Class Sales Forecast ($bn), 2010-2025; Figure 4.2 Human Insulins Class Sales Forecast ($bn), 2010-2025; Figure 4.3 Immunosuppressive Agents Class Sales Forecast ($bn), 2010-2025; Figure 4.4 Autoimmune Agents Class Sales Forecast ($bn), 2010-2025; Figure 4.5 Erythropoietin Products Class Sales Forecast ($bn), 2010-2025; Figure 4.6 Immunostimulating Agents Class Sales Forecast ($bn), 2010-2025; Figure 4.7 Interferons Class Sales Forecast ($bn), 2010-2025; Figure 4.8 Pure Vaccines Class Sales Forecast ($bn), 2010-2025; Figure 4.9 Blood Coagulation Factors Class Sales Forecast ($bn), 2010-2025; Figure 4.10 Growth Hormones Class Sales Forecast ($bn), 2010-2025; Figure 4.11 Top Ten Therapy Classes Sales ($bn), 2009, 2015 & 2025; Figure 5.1 Enbrel Sales Forecast ($m), 2010-2025; Figure 5.2 Remicade Sales Forecast ($m), 2010-2025; Figure 5.3 Avastin Sales Forecast ($m), 2010-2025; Figure 5.4 MabThera/Rituxan Sales Forecast ($m), 2010-2025; Figure 5.5 Humira Sales Forecast ($m), 2010-2025; Figure 5.6 Herceptin Sales Forecast ($m), 2010-2025; Figure 5.7 Lantus Sales Forecast ($m), 2010-2025; Figure 5.8 Neulasta Sales Forecast ($m), 2010-2025; Figure 5.9 Glivec Sales Forecast ($m), 2010-2025; Figure 5.10 Epogen Sales Forecast ($m), 2010-2025; Figure 5.11 Top Ten Biotech Drugs Sales ($m), 2009, 2015 & 2025; Figure 6.1 The Top Ten Biotech Companies, Revenues ($m), 2008; Figure 6.2 The Top Ten Biotech Companies, Market Shares (%), 2008; Figure 8.1 Pharma Biotech Market Shares (%) by Country/Region, 2009; Figure 8.2 Pharma Biotech Market Shares (%) by Country/Region, 2015; Figure 8.3 Pharma Biotech Market Shares (%) by Country/Region, 2025
Companies Listed: 3SBio; Abbott; Actelion; Active Biotech; Agennix; Ambrx; Amgen; Antisense Pharma; Apotex; Ark Therapeutics; Astellas; AstraZeneca; Bayer Schering; Bayhill Therapeutics; Biodel; Biogen Idec; BioMerieux; BioVex; Bradmer; Bristol-Myers Squibb; Celgene; Centocor Ortho Biotech; Cephalon; Chong Kun Dang; Chugai; CSL; Daiichi Sankyo; Dendreon; Dompe; Dr. Reddy's Laboratories; Dynavax; Eczacibasi; Eisai; Eli Lilly; Esteve; Genentech; Genmab; GenQuest; GenVec; Genzyme; Gilead Sciences; GlaxoSmithKline; Global Solutions; Green Cross; HealthCare Asia; Hexal; Hospira; Human Genome Sciences; ImClone Systems; Immunex; Immunomedics; Introgen Therapeutics; Ipsen; JCR Pharmaceuticals; Jiangsu Yanshen; Johnson & Johnson; Kissei; Kowa; LG Life Sciences; LipoNova; MacroGenics; Medice; Menarini; Merck & Co.; MGI Pharma; Mitsubishi Tanabe; MolMed; Morphotek; NeoPharm; Northwest Biotherapeutics; Novartis; NovaRx; Novo Nordisk; Otsuka; Oxford BioMedica; Pfizer; Pharming; Pierre Fabre; ProCellEx; Protalix Biotherapeutics; Protein Sciences; Rentschler; Roche; Sandoz; Sanofi-Aventis; Santen; Schering-Plough; SemBioSys; Shanghai Celgen; Stada; Takara Bio; Takeda; Teva; Transgene; UCB; United Therapeutics; Viventia Biotech; Wilex; Wyeth; XOMA; Zenyaku Kogyo

More Global Biopharmaceuticals Reports

Global Biosimilars Market Forecast to 2015 by RNCOS
The biosimilars industry has been growing stupendously across the globe for past few years. Increasing healthcare costs and rising aging population are driving the industry, ...

Biosimilars: Current Situation & Future Prospects, Worldwide by JustPharmaReports.com
The engine of the biosimilar sector is the same as with small molecule drugs, patent expiry. On this basis, prospects for biosimilars look good, with ...

World Biological Drugs Market 2012-2022 by Visiongain
Where is the market for biological drugs heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions. Our new study ...

Global Biosimilars: A return to optimism? by Espicom Healthcare Intelligence
Despite some commentators predicting a muted or near nonexistent market for advanced biosimilars, many companies - and some surprising names - are positioning themselves for ...

Cell Culture: The World Market for Media, Sera and Reagents, 3rd. Edition by Kalorama Information
Several cell culture-derived biopharmaceutical drugs were launched in the US and European markets in 2010. Biopharmaceuticals (recombinant proteins, monoclonal antibody and nucleic acid-based products) represent ...

See all reports like this >>

Global Pharmaceutical Biotech Market 2010-2025

Share this report

Other tasks

Research Assistance

Related Markets

Biopharmaceuticals Reports

Free Alert Me service